Utilization of the Viracor® Assay for Valganciclovir Prophylaxis in CMV High Risk Kidney Transplant Recipients

Completed

Conditions studied: Kidney Transplant; Complications

In brief

The purpose of this study is to evaluate whether the use of the Viracor® CMV immunity assay at 6 months post-transplant in CMV high risk kidney transplant recipients would help identify those patients at higher risk of post-prophylaxis CMV viremia or disease and thereby select those patients in which a longer duration of valganciclovir prophylaxis would be beneficial.

Key facts

Study ID

NCT05238220

Run by

Piedmont Healthcare

People needed

37

Starts

2021-01-04

Expected to finish

2022-06-30

Last updated by the study team

2024-11-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Able to provide consent
• Kidney Transplant Recipients
• Classified as CMV high risk at time of transplant (donor CMV IgG positive and recipient CMV IgG negative)

You may not qualify if…

• none

Where it is running

• Piedmont Atlanta Hospital — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.